

Société Tunisienne de Psychiatrie de l'Enfant et l'Adolescent Tunisian Association for Child and Adolescent Psychiatry

VISA 2014T0103APSF1 RIB: 08005010052020105621

Présidents d'honneur Feu Mohamed Béchir Halayem Farhat Ghribi

Past President: Yousr Moalla moalla_yousr@medecinesfax.org

Président : Asma Bouden asmabouden@gmail.com 70162218/22324576

Vice-président : Fatma Charfi fatma.charfi@fmt.utm.tn

Secrétaire général Khaoula Khemakhem khamkhemkhawla@yahoo.fr

Secrétaire général adj : Abir Ben Hamouda abirovabenhamouda@yahoo.fr

Trésorier : Ons Nouira ons.nouira@yahoo.fr

Trésorier adjoint : Jaweher Boudabous boudabous_jaweher@yahoo.fr

Membres : Hela Ben Abid helabenabid1988@gmail.com

Imene Chaabene imen_chaabane@yahoo.fr

Randaline Ayoub ayoub.randaline@gmail.com

To the Expert Committee on the Selection and Use of Essential Medicines World Health Organization 1211 Geneva 27, Switzerland

Subject: Letter of support for the inclusion of methylphenidate on the WHO Model List of Essential Medicines

Dear Members of the Committee,

As an association of child and adolescent psychiatrists working in the field of mental health in Tunisia, we would like to express our **strong support** for the inclusion of **methylphenidate** on the **World Health Organization's Model List of Essential Medicines**.

In Tunisia, attention-deficit/hyperactivity disorder (ADHD) remains a condition that is still widely underdiagnosed and insufficiently managed, despite its significant impact on the lives of children, adolescents, and their families. Although precise national epidemiological data are lacking, regional prevalence studies suggest that the frequency of ADHD is comparable to that observed internationally.

Furthermore, **specialized child and adolescent psychiatric services** remain scarce, particularly outside major cities. Access to **methylphenidate**, a first-line treatment recommended by many leading international medical societies, is especially **limited**: its availability is confined to a few hospital settings, and it is **not included in the national list of reimbursed medicines**. As a result, many children are deprived of a treatment to which they are rightfully entitled.

The inclusion of methylphenidate on the WHO Model List of Essential Medicines would send a **strong signal** to Tunisian health authorities, encouraging them to **recognize the importance of this treatment** and to **facilitate its availability** in a secure and regulated manner.

Such international recognition would also contribute to **reducing the stigma** associated with ADHD, **promoting evidence-based care**, and **integrating this treatment into national mental health policies**, which are currently being strengthened.

We thank you for your attention to this important matter and remain at your disposal for any additional information you may require.

Adresse: 26 Rue Samaoul, Mutuelleville, Tunis Email: pedopsytuuisienne@gmail.com